help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on July 11, 2003, doi:10.1164/rccm.200208-794OC
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200208-794OCv1
168/8/968    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qiu, Y.
Right arrow Articles by Jeffery, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qiu, Y.
Right arrow Articles by Jeffery, P. K.
American Journal of Respiratory and Critical Care Medicine Vol 168. pp. 968-975, (2003)
© 2003 American Thoracic Society

Biopsy Neutrophilia, Neutrophil Chemokine and Receptor Gene Expression in Severe Exacerbations of Chronic Obstructive Pulmonary Disease

Yusheng Qiu, Jie Zhu, Venkata Bandi, Robert L. Atmar, Keith Hattotuwa, Kay K. Guntupalli and Peter K. Jeffery

Lung Pathology, Department of Gene Therapy, Imperial College, Royal Brompton Hospital, London, United Kingdom; and Department of Medicine and Department of Molecular Virology and Microbiology, Baylor College of Medicine, Ben Taub General Hospital, Houston, Texas

Correspondence and requests for reprints should be addressed to Peter K. Jeffery, F.R.C.Path, D.Sc., Ph.D., Lung Pathology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. E-mail: p.jeffery{at}ic.ac.uk


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We have applied immunohistology and in situ hybridization to bronchial biopsies of patients with chronic obstructive pulmonary disease (COPD) to examine neutrophil recruitment and to determine neutrophil chemoattractant and CXC receptor (CXCR) 1 and CXCR2 gene expression associated with acute severe exacerbations. Cells were counted in endobronchial biopsies of (1) patients with COPD intubated for exacerbations (E-COPD; n = 15), (2) those with COPD in a stable phase of their disease (S-COPD; n = 7), and (3) nonsmoker surgical control subjects intubated for a nonrespiratory surgical procedure (n = 15). In comparison with the nonrespiratory surgical procedure and S-COPD groups, neutrophilia and gene expression for epithelial-derived neutrophil attractant-78 (CXCL5), interleukin-8 (CXCL8), CXCR1, and CXCR2 were each upregulated in the E-COPD group (p < 0.01); compared with the S-COPD group, by 97-, 6-, 6-, 3-, and 7-fold, respectively (p < 0.01). In E-COPD, there was a significant positive association between the number of neutrophils and CXCR2 mRNA–positive cells (r = 0.79; p < 0.01) but not between the number of neutrophils and CXCR1 mRNA–positive cells. At the time of sampling of the mucosa, there was no association between neutrophil number and either the length of intubation or viral infection. Thus, in COPD, in addition to CXCL8 and CXCR1, CXCL5 and CXCR2 appear to play important roles in the airway neutrophilia characteristic of severe exacerbations.

Key Words: chemokines • CXCL5, CXCL8, CXCR1, CXCR2 • COPD • neutrophils

It has been estimated that 44 million people currently suffer from chronic obstructive pulmonary disease (COPD) worldwide, and it is predicted that by 2020 it will become the third leading cause of death, up from its current sixth place (1). As lung function worsens, patients with COPD become increasingly prone to exacerbations, a major reason for hospital admission and a relatively large component of health care cost (2).

Pathologically, COPD is characterized by chronic inflammation and remodeling throughout the conducting airways, parenchyma, and pulmonary vasculature (3–5). In stable COPD, there is a characteristic infiltration of the bronchial mucosa with increased numbers of CD8+ T lymphocytes and macrophages (6–9), but not neutrophils (6). However, in an exacerbation in mild COPD and in severe disease there is an increase in the number of neutrophils and their markers in the airways (10–18). Also, in exacerbations in mild COPD, there is an accumulation of eosinophils in the mucosa (10), likely due to the reported upregulation of the eosinophil chemoattractant regulated upon activation, normal T cell expressed and secreted, whose effects may be mediated through chemokine receptor (CCR) 3 (19).

The chemoattractants and receptors influencing the recruitment and accumulation of tissue neutrophils in exacerbations of COPD, and how these changes relate to infection and symptoms, are poorly understood (16, 17, 20).

Chemoattraction of neutrophils is thought to occur via the production of a number of neutrophil-selective chemokines including growth-related protein-{alpha}, -ß, and -{gamma} (CXCL1–3), epithelial-derived neutrophil attractant-78 (CXCL5), human granulocyte chemotactic protein-2 (CXCL6), neutrophil-activating peptide-2 (CXCL7), and interleukin-8 (CXCL8) (20–25). Each of the aforementioned belongs to the same CXC chemokine family, characterized by separation of the conserved cysteines by a single amino acid and containing the Glu-Leu-Arg amino acid motif of glutamic acid-leucine-arginine and the designated gene SCYb (small secreted cytokine) (23, 26). Among them, CXCL8 has been relatively well characterized as a neutrophil chemoattractant and activating cytokine for neutrophils and to a lesser extent for eosinophils (20, 24, 26). Epithelial cells, endothelial cells, fibroblasts, alveolar macrophages, and neutrophils themselves are able to release CXCL8 in response to proinflammatory molecules such as tumor necrosis factor, IL-1, and endotoxin (20, 22).

In contrast, the roles of other CXC chemokines in airway inflammation have been less well studied. Imaizumi and coworkers examined CXCL5 expression in cultured human endothelial cells stimulated with IL-1{alpha}: these authors reported that CXCL5 and CXCL8 share certain features of regulation and have overlapping biological activities, including the capacity to induce neutrophil adhesiveness (25). There are no published biopsy data on the relative expression and upregulation of these two neutrophil chemoattractants in the bronchial mucosa of patients with COPD, and none in exacerbations. Moreover, although data have been published on CXCR3 expression (27), there has been no previous report in COPD of tissue CXCR1 and CXCR2 expression, the relevant receptors on which these neutrophil chemoattractant ligands act (21).

Our premise for the present study was that an improved understanding of the mechanisms responsible for initiating and maintaining the increased neutrophilia in acute exacerbations may lead to more effective control and prevention of such exacerbations, the frequency of which is associated with accelerated FEV1 decline (16, 28, 29). Accordingly we present the results of localization and quantification of neutrophils recruited to the airway mucosa, and the numbers of cells expressing genes for CXCL5, CXCL8, CXCR1, and CXCR2 in critically ill patients requiring intubation for the management of acute severe exacerbations of COPD. We have compared the counts with those of patients intubated in the course of nonrespiratory elective surgery and with bronchial biopsies of patients with mild stable COPD. Some of the results of this study have been reported previously in abstract form (30, 31).


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Subjects
Three groups of subjects (see Table 1) were biopsied: (1) the nonsmoker surgical control subjects (NSC; n = 15) were nonatopic nonsmokers with normal lung function (i.e., FEV1 > 80% of predicted; FEV1/FVC > 70%) who were having a surgical procedure performed under general anesthesia for nonbronchopulmonary disease (hysterectomy or cholecystectomy). Biopsies were taken immediately after intubation and before the infusion of prophylactic antibiotics; (2) patients with stable COPD (S-COPD, n = 7) were defined by the Global Initiative for COPD (1) and were smokers (60 ± 7.5 pack-years) with chronic irreversible airflow obstruction with FEV1 < 80% of predicted (i.e., mean ± SEM = 51 ± 3.3% of predicted) and FEV1/FVC < 70% (i.e., mean ± SEM = 53 ± 7.5%). These patients were biopsied under sedation; and (3) smokers (61 ± 4.9 pack-years) with COPD admitted to hospital as emergencies (E-COPD) due to a severe exacerbation (FEV1 < 50% of predicted; n = 15) (1) and with a mean FEV1 of 36 ± 2.4% of predicted and an FEV1/FVC of 35 ± 3.3%; they all required intubation and mechanical ventilation for respiratory or right heart failure.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Summary of patient groups

 
Bronchoscopy and Biopsy
Biopsies from third- to fifth-order bronchi were fixed immediately in 10% formaldehyde and processed to paraffin wax.

Microbiology
Haemophilus influenzae in bronchial biopsies was detected by immunohistostaining and hybridization techniques described in a previous publication (32). The methods for detection and identification of respiratory tract viruses have been previously described by Atmar and coworkers (33).

Immunohistology
Mouse monoclonal antibodies, raised against human neutrophil intracellular elastase (Ne) (M0725; Dako, Ely, UK), were applied to the tissue sections and the results were visualized by a validated EnVision–alkaline phosphatase technique (Dako).

In Situ Hybridization
Riboprobes were applied to detect intracytoplasmic mRNA for chemokines CXCL5 and CXCL8 and for receptors CXCR1 and CXCR2 (19, 34). The sizes (base pairs [bp]) and vectors of the probes were as follows: CXCL5 (220 bp; PBSIISK-), CXCL8 (246 bp; PGEM-3Z), CXCR1 (1.1 kbp; PBSIISK-), and CXCR2 (1.1 kbp; PBSIISK-). Sense probes were used as appropriate negative control subjects.

Quantification and Data Analysis
The areas of subepithelium, excluding muscle, gland, and large vessel, were measured. Immunopositive and in situ hybridization-positive cells were counted at x200 magnification. An eyepiece graticule was used to "point count" and assess the percentage of epithelium expressing mRNA for CXCL5 (35).

Statistical Analysis
The Mann–Whitney U test was applied to nonnormally distributed data to test for differences in area profile cell counts between E-COPD, S-COPD, and NSC groups and between the E-COPD subgroups with and without viral infection. The Student t test was used for the analysis of point count data and epithelial CXCL5 expression. The Spearman rank correlation test was used to determine the association between parameters and to examine that between length of intubation and number of tissue neutrophils in the E-COPD group. A p value less than 0.05 was accepted as statistically significant in the Mann–Whitney U test and t test. For the Spearman rank correlation, a Bonferroni correction for multiple comparisons was applied and a p value less than 0.02 was used as the threshold for statistical significance. See the online supplement for additional detail on the methods used in this study.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Clinical Findings
The characteristics of the subjects and patients examined are shown in Table 1. There was no significant difference in age between the two COPD groups. However, the ages of the patients in both COPD groups were greater than those of patients in the NSC group (p < 0.05). Both the FEV1% of predicted and FEV1/FVC values of the COPD groups was significantly lower than those of the NSC group (p < 0.01). As expected, the lowest FEV1% of predicted and FEV1/FVC values were found among the patients with E-COPD. The most recently obtained outpatient results of pulmonary function tests, obtained within 120 days of the exacerbation, were used for these data. Thirteen of the 15 biopsies tested from patients with acute severe exacerbations of COPD, but none from the control subjects, were positive for nontypeable Haemophilus influenzae detected by monoclonal antibody (32). Seven of the patients with E-COPD (i.e., 47%) were positive for acute viral infections, as demonstrated by viral cultures or polymerase chain reaction. No virus was isolated from either the NSC or S-COPD group.

Immunohistologic Findings
Ne-positive cells were seen in both the epithelium and subepithelial tissue (Figure 1) . In both zones, the number of Ne+ cells was significantly higher in the E-COPD group than in either the S-COPD or NSC group (p < 0.01; Table 2) . In contrast, the number of Ne+ cells in the S-COPD group was low and similar to that in the NSC group.



View larger version (126K):
[in this window]
[in a new window]
  		Figure 1. Neutrophil elastase positivity in the airway mucosa of a patient with a severe exacerbation of chronic obstructive pulmonary disease (COPD). Original magnification, x200.

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. Counts of positive cells per area: median and range

 
In dividing the E-COPD group into those with and without detectable virus infection, there appeared to be more neutrophils in those with virus (n = 6, median = 196/mm2 subepithelium and 0.36/0.1 mm2 epithelium) than without (n = 7, 68/mm2 subepithelium and 0.25/0.1 mm2 epithelium), but this was due to a particularly high count in one patient and the between-group differences were not significant statistically (p = 0.20).

Gene Expression
Whereas the sense probes for CXCL5, CXCL8, CXCR1, and CXCR2 mRNA were negative (Figure 2) , the antisense probes for the four genes were positive in each of the three study groups (Figures 3– 5) . The staining intensity for each parameter was greatest in the E-COPD group. The intensity of CXCR2 mRNA expression was stronger than that of CXCR1 in both epithelial and subepithelial compartments. There was no epithelial expression for CXCR1 in any group. If present, epithelial CXCR2 was weakly expressed and then only in the E-COPD group. Expression of CXCL8 was similar to that of CXCR2 but, in addition, was weakly expressed in the S-COPD group. In contrast, CXCL5 was intensely expressed in the E-COPD group in both epithelium and subepithelium. For the assessment of epithelial CXCL5 expression, on average, 7.0% (SEM = ± 2.8%) of the epithelium of the NSC group showed expression for CXCL5. In the S-COPD group this value had increased to 21% (SEM = ± 6.6%) (p < 0.01 compared with NSC) and in the E-COPD group it was 58% (SEM = ± 6.1%; p < 0.01 compared with NSC and S-COPD groups).



View larger version (139K):
[in this window]
[in a new window]
  		Figure 2. Sense control for the CXC receptor (CXCR) 2 gene probe, showing the absence of gene expression. Original magnification, x200.

 


View larger version (63K):
[in this window]
[in a new window]
  		Figure 3. Cells positive for CXCL8 messenger RNA (mRNA) in the airway mucosa of (A) a patient with stable COPD (S-COPD) and (B) a patient with a severe exacerbation of COPD (E-COPD). There are more CXCL8-positive cells and the intensity of expression is greater in (B). Original magnification, x200.

 


View larger version (60K):
[in this window]
[in a new window]
  		Figure 5. Cells positive for CXCR2 mRNA in the airway mucosa of (A) a patient with S-COPD and (B) a patient with an exacerbation. The latter shows more positive cells and greater intensity of gene expression than the former. Original magnification, x200.

 


View larger version (61K):
[in this window]
[in a new window]
  		Figure 4. Cells positive for CXCL5 mRNA in the airway mucosa of (A) a patient with S-COPD and (B) a patient with a severe exacerbation. The number of positive cells and the intensity of expression are far greater, relative to CXCL8, in both the epithelium and subepithelium and greater than that seen in S-COPD. Original magnification, x200.

 
In the subepithelium, the counts for CXCL5, CXCL8, CXCR1, and CXCR2 mRNA-positive cells are shown in Table 2 and Figures 6A–6D . The numbers of cells positive for CXCL5, CXCL8, CXCR1, and CXCR2 in the E-COPD group were approximately five, six, three, and six times higher than those of the NSC (p < 0.01) and S-COPD groups, respectively (p < 0.01 for CXCL5 and CXCR2, p < 0.05 for CXCL8 and CXCR1). There were no significant differences between the S-COPD and NSC groups with respect to cells expressing any of the four genes.






View larger version (69K):
[in this window]
[in a new window]
  		Figure 6. (A) Counts of CXCL8 mRNA–positive cells in the subepithelium of biopsies taken from intubated nonsmoker surgical control subjects (NSC), patients with S-COPD, and those intubated for severe E-COPD. Median values are indicated. (B) Counts of CXCL5 mRNA–positive cells in the subepithelium of NSC, patients with S-COPD, and those with severe E-COPD. (C) Counts of CXCR1 mRNA–positive cells in the subepithelium: NSC, patients with S-COPD, and those with severe E-COPD. (D) Counts of subepithelial CXCR2 mRNA–positive cells: NSC, patients biopsied with S-COPD, and those with severe E-COPD.

 
In comparing the numbers of positive cells for CXCL5, CXCL8, CXCR1, and CXCR2 mRNA in each of the three study groups, the number of CXCL5 mRNA-positive cells was greater than any other. In the NSC group, the number of CXCL5-positive cells was about eight-, three-, and fourfold higher than those of CXCL8-, CXCR1-, and CXCR2-positive cells (p < 0.05). In S-COPD this pattern remained but the differences were not significant statistically. In the E-COPD group the number of CXCL5-positive cells was approximately three times higher than any other parameter (p < 0.05).

The numbers of subepithelial CXCL5, CXCL8, and CXCR2 mRNA-positive cells were similar in the patients with E-COPD with and without evidence of viral infection. There were, however, significantly fewer CXCR1 mRNA-positive cells in the virally infected subjects than in those without infection (median, 53 versus 222 cells per mm2 subepithelium, respectively; p < 0.05).

Correlations
There were no significant associations between the numbers of Ne-positive cells and the numbers of cells expressing CXCL5, CXCL8, CXCR1, and CXCR2 in either the NSC or S-COPD group. However, among the patients with E-COPD there were significant and positive associations between Ne-positive cells and cells with mRNA positive for CXCL5, CXCL8, and CXCR2 (Spearman rank correlation: r = 0.61, 0.59, and 0.79, respectively; p < 0.02 for each). There was also a significant correlation between CXCL8-positive cells and CXCR1-positive cells (r = 0.69, p < 0.01; Figure 7) but not between CXCL8- and CXCR2-positive cells (r = 0.46, p = 0.07). In contrast, the number of CXCL5-positive cells was significantly associated with CXCR2-positive cells (r = 0.66, p = 0.01) (Figure 8) but not with CXCR1-positive cells (r = 0.49, p = 0.06). A significant correlation was also found between CXCL8-positive cells and CXCL5-positive cells (r = 0.71, p < 0.01). There was no significant association between the number of Ne-positive cells and length of intubation in either all the patients with E-COPD (n = 15, r = –0.62; p = 0.03) or those in this group who had Ne-positive cells above the median (n = 7, r = –0.68; p = 0.09).



View larger version (15K):
[in this window]
[in a new window]
  		Figure 7. Correlation between CXCL8 mRNA–positive cells and CXCR1 mRNA–positive cells in the subepithelium of patients intubated for severe E-COPD.

 


View larger version (14K):
[in this window]
[in a new window]
  		Figure 8. Correlation between CXCL5 mRNA–positive and CXCR2 mRNA–positive cells in the subepithelium of patients with severe E-COPD.

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We have used endobronchial biopsies and counted neutrophils and cells expressing the genes for neutrophil chemoattractants and their complementary receptors in patients with COPD hospitalized for severe exacerbations. The results show that compared with patients with stable COPD (S-COPD) and also with nonsmoker control subjects (NSC), patients with COPD with severe exacerbations (E-COPD) have significantly increased numbers of neutrophils and that this is associated with increases in CXCL5, CXCL8, and CXCR2 but not in CXCR1 expression. Moreover, the increased numbers of neutrophils in E-COPD were not associated with length of intubation. To our knowledge, this is the first study of these tissue parameters in COPD in relation to an acute severe exacerbation.

Previously published studies demonstrate that neutrophils form a major component of the inflammatory infiltrate in exacerbations of COPD (10, 13, 15) and when disease is severe (11, 18). It has been hypothesized that neutrophils are stimulated, activated, and recruited through upregulation and binding of a number of CXC chemokines to their complementary receptors, notably CXCR1 and CXCR2 (21, 36–38). Until now, this has not been tested by direct examination of airway tissues in exacerbations of COPD and our results provide supportive evidence of a role for these two neutrophil chemoattractants and major receptors in exacerbation.

It has been considered, in neutrophil chemotaxis, that neutrophil cell surface CXCR1 is highly selectively bound and activated by CXCL8 whereas CXCR2 responds not only to CXCL8 but also to other chemoattractants including CXCL1, CXCL5, and CXCL7 (36, 38). In a previous study of the intrapulmonary airway mucosa in lungs resected for tumor, smokers with stable COPD showed upregulation of epithelial CXCL8 (39). Our study, of subepithelial CXCL8, in stable disease, does not. However, we confirm the previously reported lack of correlation between neutrophil numbers and CXCL8 expression. We report additional data to show that, in stable disease, there is also no significant correlation between neutrophilia and subepithelial CXCL5 expression, another putative neutrophil chemoattractant. In contrast in the biopsies of patients with a severe exacerbation of COPD, we do demonstrate positive correlations between neutrophils and cells positive for both CXCL8 mRNA (Spearman rank correlation: r = 0.59; p = 0.02) and CXCL5 mRNA (r = 0.61; p = 0.02). Moreover, our findings in the bronchial mucosa of all groups demonstrate that CXCL5 rather than CXCL8 is the dominant CXC chemoattractant.

CXCL5 is a 78-residue chemokine originally isolated from the supernatant of a lung Type II alveolar epithelial cell line stimulated by IL-1, tumor necrosis factor-{alpha}, and by both viable and heat-killed Mycoplasma hominis (40–42). Our results demonstrate that CXCL5 is upregulated in exacerbations of COPD. In addition to epithelial cells, monocytes, neutrophils, fibroblasts, endothelial cells, platelets, and tumor cells have also been demonstrated to be a source for CXCL5 (26). The intensity of expression of epithelial CXCL5 mRNA indicates the epithelium is clearly one important source of this chemokine in exacerbations of COPD and, once released, CXCL5 may target neutrophils, likely stimulating their epithelial chemotaxis by binding CXCR2 (43). Several studies support a role for CXCL5 in neutrophil chemotaxis (44, 45). Other roles for CXCL5 (e.g., as an angiogenic factor in pulmonary fibrosis or non-small cell lung cancer) are likely to emerge in future (46, 47).

The receptor CXCR1 is thought to be activated by CXCL8 and is a major receptor responsible for chemotaxis, superoxide production, and phospholipase D activation in response to CXCL8 (26, 37). We show that the numbers of CXCR1 and CXCR2 mRNA–positive cells in the bronchial mucosa of patients with stable COPD were similar. However, the extent of upregulation and the intensity of CXCR2 mRNA expression in E-COPD are considerably greater than that of CXCR1. Moreover, the increase in the number of neutrophils is significantly and positively associated with increased expression of CXCR2 (r = 0.79; p < 0.02) and not with CXCR1. As CXCR2 may also be expressed by activated T lymphocytes, mast cells, dendritic cells, macrophages, basophils, and eosinophils, these cells may also be recruited to the mucosa via binding of CXCR2. Overall, the data we report are supportive of major roles for both CXCL5 and CXCR2 in controlling tissue neutrophilia in severe exacerbations of COPD. Our results provide data additional to that published for CXCR3 and CXCL10 in the inflammation of COPD (27).

Finally, we faced several difficulties in the interpretation of our results, for example: (1) age, (2) the undetermined extent of the contribution to neutrophilia made by intubation and mechanical ventilation per se, (3) the effect of steroid treatment, (4) the role of infection, and (5) the numbers of neutrophils in the S-COPD group. Taking each in turn: (1) The patients with E-COPD were significantly older in comparison with the NSC group. We attempted to reduce this difference by exclusion of all patients below the age of 40 years. Also, we consider that the differences in inflammatory indices for the exacerbated group are likely not due to age alone, as they are controlled for by the S-COPD group, which was of similar age to the E-COPD group; (2) the lag periods between initiation of the intubation procedure and biopsy differed between the NSC and E-COPD groups: in the former, biopsies were taken within minutes and in the latter at times up to 26 hours after the start of intubation. There have been no studies that investigate the effect of intubation time on neutrophil numbers in COPD. However, in asthma there have been some weak and variable associations reported between time of intubation and neutrophilia and these have been debated (48–50). We found no association between the length of intubation and the increase of neutrophil numbers, either in the entire E-COPD group or in a subset with relatively high numbers of neutrophils; (3) it has been reported that there are increased numbers of neutrophils in bronchial biopsies of patients receiving long-term high-dose treatment with glucocorticoids (at least in severe asthma) and that the effect is mediated via reduction of neutrophil apoptosis (51–53). In our study of COPD, only three patients in the E-COPD group had received treatment with long-term low-dose inhaled steroids. The counts of neutrophils in their biopsies showed that the numbers, although increased with respect to S-COPD and NSC control subjects, were less than those of subjects who had not received steroid treatment. It is, therefore, unlikely that the increased number of neutrophils we observed was related to steroid treatment; (4) infection is considered a major determinant of airway neutrophilia in exacerbations of COPD and asthma (13, 29, 54). In the present study, 13 of the 15 subjects in the E-COPD group were positive for nontypeable Haemophilus influenzae and 7 (47%) were positive for acute viral infections. The study by Seemungal and co-workers demonstrates that 40% of acute exacerbations in COPD are associated with respiratory viral infection (29). However, we compared neutrophil numbers in the E-COPD group with and without positive viral culture and found no significant differences. These findings agree with a study of 14 patients by Aaron and co-workers (13), who reported that markers of neutrophilic inflammation increase in the airways of patients with an acute exacerbation of COPD, yet the response occurs independently of a demonstrable viral or bacterial infection. However, our own data do not exclude the influence of bacterial infection and viral infection (such as rhinovirus) that may have been present before the time of sampling; and (5) finally, the number of neutrophils present in our S-COPD group was low (range, 0–7 neutrophils per mm2) compared with several European studies of patients with stable COPD reported in the literature, including our own (e.g., range = 0–241 neutrophils per mm2) (55). However, we confirmed the present results by restaining sections. As both the U.S. and European patients we have previously studied had COPD of similar severity, the reason for the differences in neutrophil counts is presently unclear. This encourages us to look more closely for an explanation of such regional differences in future.

In conclusion, the present study of bronchial biopsies taken in a critical care setting demonstrates that in severe exacerbations of COPD there is increased neutrophil recruitment and that this is associated with upregulation of both CXCL5 and CXCL8. Upregulation of the gene for CXCL8 correlates well with that for CXCR1 whereas CXCL5 is better associated with CXCR2 gene expression. We have highlighted putative novel roles for CXCL5 and CXCR2 in neutrophil recruitment in severe exacerbations of COPD, improving our understanding of the mechanisms responsible for the associated tissue neutrophilia.


   Acknowledgments
 
Y.Q. has no declared conflict of interest; J.Z. has no declared conflict of interest; V.B. has no declared conflict of interest; R.L.A. has no declared conflict of interest; K.H. has no declared conflict of interest; K.K.G. has no declared conflict of interest. P.K.J. has been reimbursed by GlaxoSmithKline (GSK), Astra-Zeneca (A-Z) and Merck, Sharpe & Dohme (Merck) for attending many conferences, has participated as a paid speaker in scientific meetings or courses organized and financed by various pharmaceutical companies (such as GSK, A-Z, Merck and Boehringer Ingelheim), has served as a consultant to GSK and Novartis, and has received research grants from several pharmaceutical companies over many years and currently holds research grants from GSK (approximately $750,000), Merck ($120,000), and A-Z ($140,000), the first of which includes a grant for a multicenter clinical trial, and his institution has received unrestricted grants from a wide variety of pharmaceutical companies.

The authors thank GSK, UK and the NIH for their generous support; Mr. D. Wang for statistical advice; Drs. Tim Wells and Christine Powers (previously of Glaxo, Geneva), who provided the gene probes; and the technicians at the Baylor Influenza Research Center for viral PCR and culture studies.


   FOOTNOTES
 
Supported by GSK Research and Development, UK, and by contracts N01-AI-65298 and Nibcm AI 19641, National Institute of Allergy and Infectious Diseases, NIH.

This article has an online supplement, which is accessible from this issue's table of contents online at www.atsjournals.org

Received in original form August 2, 2002; accepted in final form July 4, 2003


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Pauwels R, Anthonisen N, Barnes PJ, Buist AS, Calverley CP, Fukuchi Y, Grouse L, Hogg JC, Jenkins C, Postma DS, et al. Global initiative for chronic obstructive lung disease. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2001.
  2. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52:67–71.[Abstract/Free Full Text]
  3. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:S28–S38.[Abstract/Free Full Text]
  4. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304–1309.[Free Full Text]
  5. Peinado VI, Barbera JA, Abate P, Ramirez J, Roca J, Santos S, Rodriguez-Roisin R. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1605–1611.[Abstract/Free Full Text]
  6. O'Shaughnessy T, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852–857.[Abstract]
  7. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A, Fabbri LM. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993;147:301–306.[Medline]
  8. Lams BE, Sousa AR, Rees PJ, Lee TH. Subepthelial immunopathology of large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J 2000;15:512–516.[Abstract]
  9. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma: Giles F. Filley Lecture. Chest 2000;117:251s–260s.
  10. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646–1652.[Abstract]
  11. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri L, Donner CF, Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158:1277–1285.[Abstract/Free Full Text]
  12. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, Fabiano F. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846–850.[Abstract]
  13. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349–355.[Abstract/Free Full Text]
  14. Maestrelli P, Saetta M, Di Stefano A, Calcagni PG, Turato G, Ruggieri MP, Roggeri A, Mapp CE, Fabbri LM. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995;152:1926–1931.[Abstract]
  15. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–1613.[Abstract/Free Full Text]
  16. Wedzicha JA. Mechanisms of exacerbations. Novartis Found Symp 2001;234:84–93.[Medline]
  17. Gompertz S, Stockley RA. Inflammation–role of the neutrophil and the eosinophil. Semin Respir Infect 2000;15:14–23.[Medline]
  18. Turato G, Zuin R, Miniati M, Baraldo S, Rea F, Beghe B, Monti S, Formichi B, Boschetto P, Harari S, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105–110.[Abstract/Free Full Text]
  19. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK. Bronchial eosinophilia and gene expression for IL-4, IL-5, and eosinophil chemoattractants in bronchitis. Am J Respir Crit Care Med 2001;164:109–116.[Abstract/Free Full Text]
  20. Panina-Bordignon P, D'Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2003;9:104–110.[CrossRef][Medline]
  21. Owen C. Chemokine receptors in airway disease: which receptors to target? Pulm Pharmacol Ther 2001;14:193–202.[CrossRef][Medline]
  22. Strieter RM, Lukacs NW, Standiford TJ, Kunkel SL. Cytokines. 2. Cytokines and lung inflammation: mechanisms of neutrophil recruitment to the lung. Thorax 1993;48:765–769.[Free Full Text]
  23. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–127.[CrossRef][Medline]
  24. Strieter RM. Interleukin-8: a very important chemokine of the human airway epithelium. Am J Physiol Lung Cell Mol Physiol 2002;283:L688–L689.[Free Full Text]
  25. Imaizumi T, Albertine KH, Jicha DL, McIntyre TM, Prescott SM, Zimmerman GA. Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol 1997;17:181–192.[Abstract/Free Full Text]
  26. Wuyts A, Proost P, Van Damme J. Interleukin-8 and other CXC chemokines. In: Thomson A, editor. The cytokine handbook, 3rd ed. San Diego, CA: Academic Press; 2001. p. 271–311.
  27. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, Bellettato CM, Papi A, Corbetta L, Zuin R, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1404–1409.[Abstract/Free Full Text]
  28. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847–852.[Abstract/Free Full Text]
  29. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618–1623.[Abstract/Free Full Text]
  30. Qiu YS, Zhu J, Bandi V, Fraire AE, Guntupalli KK, Jeffery PK. Neutrophil chemokine receptor (CXCR1 and 2) gene expression and biopsy neutrophilia in severe exacerbations of chronic obstructive pulmonary disease (COPD) [abstract]. Eur Respir J 2001;18:501s.
  31. Qiu YS, Zhu J, Bandi V, Fraire AE, Hattotuwa K, Guntupalli KK, Jeffery PK. Endobronchial biopsy neutrophilia, IL-8, ENA-78 and neutrophil chemokine receptor (CXCR1 and CXCR2) gene expression in severe exacerbations of COPD [abstract]. Eur Respir J 2002;20:377s.[CrossRef]
  32. Bandi V, Apicella MA, Mason E, Murphy TF, Siddiqi A, Atmar RL, Greenberg SB. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001;164:2114–2119.[Abstract/Free Full Text]
  33. Atmar RL, Guy E, Guntupalli KK, Zimmerman JL, Bandi VD, Baxter BD, Greenberg SB. Respiratory tract viral infections in inner-city asthmatic adults. Arch Intern Med 1998;158:2453–2459.[Abstract/Free Full Text]
  34. Wilkinson DG. In situ hybridization: a practical approach. Oxford: Oxford University Press; 1992.
  35. Aherne WA, Dunnill MS. Point counting and morphometry. In: Aherne WA, Dunnill MS, editors. Morphometry. London: E. Arnold; 1982. p. 33–45.
  36. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI. Characterization of two high-affinity human interleukin-8 receptors. J Biol Chem 1992;267:16283–16287.[Abstract/Free Full Text]
  37. Chuntharapai A, Kim KJ. Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J Immunol 1995;155:2587–2594.[Abstract]
  38. Wuyts A, Van Osselaer N, Haelens A, Samson I, Herdewijn P, Ben Baruch A, Oppenheim JJ, Proost P, Van Damme J. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry 1997;36:2716–2723.[CrossRef][Medline]
  39. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000;190:619–626.[CrossRef][Medline]
  40. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991;174:1355–1362.[Abstract/Free Full Text]
  41. Lukacs NW, Kunkel SL, Allen R, Evanoff HL, Shaklee CL, Sherman JS, Burdick MD, Strieter RM. Stimulus and cell-specific expression of C-X-C and C-C chemokines by pulmonary stromal cell populations. Am J Physiol 1995;268:L856–L861.
  42. Kruger T, Baier J. Induction of neutrophil chemoattractant cytokines by Mycoplasma hominis in alveolar Type II cells. Infect Immun 1997;65:5131–5136.[Abstract]
  43. Bozic CR, Gerard NP, Gerard C. Receptor binding specificity and pulmonary gene expression of the neutrophil-activating peptide ENA-78. Am J Respir Cell Mol Biol 1996;14:302–308.[Abstract]
  44. Colletti LM, Kunkel SL, Walz A, Burdick MD, Kunkel RG, Wilke CA, Strieter RM. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat: the role of epithelial neutrophil activating protein. J Clin Invest 1995;95:134–141.
  45. Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL, Walz A, Hudson LD, Martin TR. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:602–611.[Abstract]
  46. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:2239–2242.[Abstract/Free Full Text]
  47. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998;102:465–472.[Medline]
  48. Lamblin C, Gosset P, Tillie-Leblond I, Saulnier F, Marquette CH, Wallaert B, Tonnel AB. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med 1998;157:394–402.
  49. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biological significance. Am J Respir Crit Care Med 2000;161:1185–1190.[Abstract/Free Full Text]
  50. Tillie-Leblond I, Pugin J, Marquette CH, Lamblin C, Saulnier F, Brichet A, Wallaert B, Tonnel AB, Gosset P. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med 1999;159:487–494.[Abstract/Free Full Text]
  51. Wenzel SE, Szefler SJ, Leung DYM, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:737–743.[Abstract/Free Full Text]
  52. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils: separation of survival and activation outcomes. J Immunol 1995;154:4719–4725.[Abstract]
  53. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422–4428.[Abstract]
  54. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843–852.[CrossRef][Medline]
  55. Gamble E, Pavord I, Vignola AM, Kroegel C, Morell F, Hansell TT, Compton C, Troy S, Edelson JD, Amit O, et al. Inflammatory cell quantification in bronchial biopsies (BB) in COPD: evaluation to 100 microns depth vs. all intact subepithelium. Eur Respir J 2002;20(Suppl):403s.



This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. S. Zaheer, R. Koetzler, N. S. Holden, S. Wiehler, and D. Proud
Selective Transcriptional Down-Regulation of Human Rhinovirus-Induced Production of CXCL10 from Airway Epithelial Cells via the MEK1 Pathway
J. Immunol., April 15, 2009; 182(8): 4854 - 4864.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Yanagisawa, H. Sugiura, T. Yokoyama, T. Yamagata, T. Ichikawa, K. Akamatsu, A. Koarai, T. Hirano, M. Nakanishi, K. Matsunaga, et al.
The Possible Role of Hematopoietic Cell Kinase in the Pathophysiology of COPD
Chest, January 1, 2009; 135(1): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
T. Seemungal, A. Sykes, and and the ICEAD Contributors
Recent advances in exacerbations of COPD
Thorax, October 1, 2008; 63(10): 850 - 852.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
K. F. Chung and I. M. Adcock
Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction
Eur. Respir. J., June 1, 2008; 31(6): 1334 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Tsoumakidou, I. K. Demedts, G. G. Brusselle, and P. K. Jeffery
Dendritic Cells in Chronic Obstructive Pulmonary Disease: New Players in an Old Game
Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1180 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. C. Newcomb, U. S. Sajjan, D. R. Nagarkar, Q. Wang, S. Nanua, Y. Zhou, C. L. McHenry, K. T. Hennrick, W. C. Tsai, J. K. Bentley, et al.
Human Rhinovirus 1B Exposure Induces Phosphatidylinositol 3-Kinase-dependent Airway Inflammation in Mice
Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1111 - 1121.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. A. Falk, O. A. Minai, and Z. Mosenifar
Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. A. Wedzicha and J. R. Hurst
Structural and Functional Co-conspirators in Chronic Obstructive Pulmonary Disease Exacerbations
Proceedings of the ATS, December 1, 2007; 4(8): 602 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
A. Sykes, P. Mallia, and S. L. Johnston
Diagnosis of Pathogens in Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 642 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. C. Newcomb, U. S. Sajjan, D. R. Nagarkar, A. M. Goldsmith, J. K. Bentley, and M. B. Hershenson
Cooperative effects of rhinovirus and TNF-{alpha} on airway epithelial cell chemokine expression
Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L1021 - L1028.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. W. Chapman, M. Minnicozzi, C. S. Celly, J. E. Phillips, T. T. Kung, R. W. Hipkin, X. Fan, D. Rindgen, G. Deno, R. Bond, et al.
A Novel, Orally Active CXCR1/2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary Inflammation
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 486 - 493.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Wiehler and D. Proud
Interleukin-17A modulates human airway epithelial responses to human rhinovirus infection
Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L505 - L515.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
B. R. Celli and P. J. Barnes
Exacerbations of chronic obstructive pulmonary disease
Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G. Turato, S. Baraldo, R. Zuin, and M. Saetta
The laws of attraction: chemokines, neutrophils and eosinophils in severe exacerbations of asthma
Thorax, June 1, 2007; 62(6): 465 - 466.
[Full Text] [PDF]

Home page
 ThoraxHome page
Y. Qiu, J. Zhu, V. Bandi, K. K Guntupalli, and P. K Jeffery
Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma
Thorax, June 1, 2007; 62(6): 475 - 482.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. K. Bentley, D. C. Newcomb, A. M. Goldsmith, Y. Jia, U. S. Sajjan, and M. B. Hershenson
Rhinovirus Activates Interleukin-8 Expression via a Src/p110{beta} Phosphatidylinositol 3-Kinase/Akt Pathway in Human Airway Epithelial Cells
J. Virol., February 1, 2007; 81(3): 1186 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. Takabatake, Y. Shibata, S. Abe, T. Wada, J.-i. Machiya, A. Igarashi, Y. Tokairin, G. Ji, H. Sato, M. Sata, et al.
A Single Nucleotide Polymorphism in the CCL1 Gene Predicts Acute Exacerbations in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 875 - 885.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Mallia and S. L. Johnston
How viral infections cause exacerbation of airway diseases.
Chest, October 1, 2006; 130(4): 1203 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
U. S. Sajjan, Y. Jia, D. C. Newcomb, J. K. Bentley, N. W. Lukacs, J. J. LiPuma, and M. B. Hershenson
H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression
FASEB J, October 1, 2006; 20(12): 2121 - 2123.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. C. Look, C. L. Chin, L. J. Manzel, E. E. Lehman, A. L. Humlicek, L. Shi, T. D. Starner, G. M. Denning, T. F. Murphy, and S. Sethi
Modulation of Airway Inflammation by Haemophilus influenzae Isolates Associated with Chronic Obstructive Pulmonary Disease Exacerbation
Proceedings of the ATS, August 1, 2006; 3(6): 482 - 483.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. J. Barnes, B. Chowdhury, S. A. Kharitonov, H. Magnussen, C. P. Page, D. Postma, and M. Saetta
Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 6 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Papi, C. M. Bellettato, F. Braccioni, M. Romagnoli, P. Casolari, G. Caramori, L. M. Fabbri, and S. L. Johnston
Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1114 - 1121.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
A. Papi, F. Luppi, F. Franco, and L. M. Fabbri
Pathophysiology of Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2006; 3(3): 245 - 251.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R O'Donnell, D Breen, S Wilson, and R Djukanovic
Inflammatory cells in the airways in COPD
Thorax, May 1, 2006; 61(5): 448 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. R. Edwards, M. W. Johnson, and S. L. Johnston
Combination Therapy: Synergistic Suppression of Virus-Induced Chemokines in Airway Epithelial Cells
Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 616 - 624.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Gamble, Y. Qiu, D. Wang, J. Zhu, A. M. Vignola{dagger}, C. Kroegel, F. Morell, T. T. Hansel, I. D. Pavord, K. F. Rabe, et al.
Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design
Eur. Respir. J., February 1, 2006; 27(2): 293 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. C. Rose and J. A. Voynow
Respiratory Tract Mucin Genes and Mucin Glycoproteins in Health and Disease
Physiol Rev, January 1, 2006; 86(1): 245 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
Y. Chiba, M. Murata, H. Ushikubo, Y. Yoshikawa, A. Saitoh, H. Sakai, J. Kamei, and M. Misawa
Effect of Cigarette Smoke Exposure In Vivo on Bronchial Smooth Muscle Contractility In Vitro in Rats
Am. J. Respir. Cell Mol. Biol., December 1, 2005; 33(6): 574 - 581.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. C. Newcomb, U. Sajjan, S. Nanua, Y. Jia, A. M. Goldsmith, J. K. Bentley, and M. B. Hershenson
Phosphatidylinositol 3-Kinase Is Required for Rhinovirus-induced Airway Epithelial Cell Interleukin-8 Expression
J. Biol. Chem., November 4, 2005; 280(44): 36952 - 36961.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. Mallia and S. L. Johnston
Mechanisms and Experimental Models of Chronic Obstructive Pulmonary Disease Exacerbations
Proceedings of the ATS, November 1, 2005; 2(4): 361 - 366.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Farkas, M.-C. Hahn, M. Schmoczer, N. Jentsch, K. Kratzel, M. Pfeifer, and C. Schulz
Expression of CXC Chemokine Receptors 1 and 2 in Human Bronchial Epithelial Cells
Chest, November 1, 2005; 128(5): 3724 - 3734.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. R. Sabater, T. A. Lee, and W. M. Abraham
Comparative Effects of Salmeterol, Albuterol, and Ipratropium on Normal and Impaired Mucociliary Function in Sheep
Chest, November 1, 2005; 128(5): 3743 - 3749.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. A. Hewson, A. Jardine, M. R. Edwards, V. Laza-Stanca, and S. L. Johnston
Toll-Like Receptor 3 Is Induced by and Mediates Antiviral Activity against Rhinovirus Infection of Human Bronchial Epithelial Cells
J. Virol., October 1, 2005; 79(19): 12273 - 12279.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
R. Wilson
Treatment of COPD exacerbations: antibiotics
Eur. Respir. Rev., September 1, 2005; 14(94): 32 - 38.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. V. Grissell, H. Powell, D. R. Shafren, M. J. Boyle, M. J. Hensley, P. D. Jones, B. F. Whitehead, and P. G. Gibson
Interleukin-10 Gene Expression in Acute Virus-induced Asthma
Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 433 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. L. Johnston
Overview of Virus-induced Airway Disease
Proceedings of the ATS, August 1, 2005; 2(2): 150 - 156.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Chakrabarti and K. D. Patel
Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils
J. Leukoc. Biol., July 1, 2005; 78(1): 279 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. L. Chin, L. J. Manzel, E. E. Lehman, A. L. Humlicek, L. Shi, T. D. Starner, G. M. Denning, T. F. Murphy, S. Sethi, and D. C. Look
Haemophilus influenzae from Patients with Chronic Obstructive Pulmonary Disease Exacerbation Induce More Inflammation than Colonizers
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 85 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Teske, A. A. Bohn, J. F. Regal, J. J. Neumiller, and B. P. Lawrence
Activation of the aryl hydrocarbon receptor increases pulmonary neutrophilia and diminishes host resistance to influenza A virus
Am J Physiol Lung Cell Mol Physiol, July 1, 2005; 289(1): L111 - L124.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. J. Barnes and R. A. Stockley
COPD: current therapeutic interventions and future approaches
Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Tsoumakidou, N. Tzanakis, G. Chrysofakis, and N. M. Siafakas
Nitrosative Stress, Heme Oxygenase-1 Expression and Airway Inflammation During Severe Exacerbations of COPD
Chest, June 1, 2005; 127(6): 1911 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Yasuda, M. Yamaya, K. Nakayama, S. Ebihara, T. Sasaki, S. Okinaga, D. Inoue, M. Asada, M. Nemoto, and H. Sasaki
Increased Arterial Carboxyhemoglobin Concentrations in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1246 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
E M Drost, K M Skwarski, J Sauleda, N Soler, J Roca, A Agusti, and W MacNee
Oxidative stress and airway inflammation in severe exacerbations of COPD
Thorax, April 1, 2005; 60(4): 293 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes
Mediators of Chronic Obstructive Pulmonary Disease
Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. A. Voynow, B. M. Fischer, D. E. Malarkey, L. H. Burch, T. Wong, M. Longphre, S. B. Ho, and W. M. Foster
Neutrophil elastase induces mucus cell metaplasia in mouse lung
Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1293 - L1302.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Strassburg, D. Droemann, G. van Zandbergen, H. Kothe, and K. Dalhoff
Enhanced PMN response in chronic bronchitis and community-acquired pneumonia
Eur. Respir. J., November 1, 2004; 24(5): 772 - 778.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. K. Jeffery
Remodeling and Inflammation of Bronchi in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 176 - 183.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. N. Georas
Inhaled Glucocorticoids, Lymphocytes, and Dendritic Cells in Asthma and Obstructive Lung Diseases
Proceedings of the ATS, November 1, 2004; 1(3): 215 - 221.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Di Stefano, A. Capelli, and C. F. Donner
Role of Interleukin-8 in the Pathogenesis and Treatment of COPD
Chest, September 1, 2004; 126(3): 676 - 678.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Critical Care Medicine in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 239 - 253.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 301 - 313.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Saetta, S. Baraldo, and R. Zuin
Neutrophil Chemokines in Severe Exacerbations of Chronic Obstructive Pulmonary Disease: Fatal Chemo-Attraction?
Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 911 - 913.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200208-794OCv1
168/8/968    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qiu, Y.
Right arrow Articles by Jeffery, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qiu, Y.
Right arrow Articles by Jeffery, P. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2003 American Thoracic Society